PMID- 10574589
OWN - NLM
STAT- MEDLINE
DCOM- 19991221
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 96
IP  - 2
DP  - 1999 Oct 15
TI  - Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.
PG  - 115-24
AB  - Varying dosages of pentasaccharide (400-800 nmol/kg) were compared to a 250-U/kg 
      single bolus dosage of unfractionated heparin (UFH) in a dog model of 
      hemodialysis. Several laboratory assays were used to monitor the effects of 
      pentasaccharide and UFH. The pentasaccharide did not produce any anticoagulant 
      effects as measured by the activated partial thromboplastin time. However, in the 
      anti-Xa chromogenic assay and the Heptest assays, there was a dose-dependent 
      prolongation after pentasaccharide administration. In the group of dogs 
      administered 800 nmol/kg of pentasaccharide, there was a 50% decrease in the 
      thrombin antithrombin (TAT) complex level after 60 minutes on dialysis. In the 
      UFH-treated dogs, wide variations in assays were observed. There was a marked 
      elevation in the activated partial thromboplastin time and Heptest assays up to 6 
      hours after UFH administration. Both anti-Xa and anti-IIa activity was measured 
      up to 4 hours. In the TAT assay, UFH was found to have a stronger effect in 
      suppressing the formation of TAT in comparison to the pentasaccharide. These 
      results suggest that pentasaccharide can be used as a replacement for UFH in a 
      dog model of hemodialysis to keep the dialysis circuit patent. In addition, the 
      anti-Xa-based assays such as the Heptest and the chromogenic anti-Xa assays can 
      be used to monitor the effects of pentasaccharide in this model.
FAU - Hoppensteadt, D A
AU  - Hoppensteadt DA
AD  - Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, 
      USA. dhoppen@wpo.it.luc.edu
FAU - Jeske, W P
AU  - Jeske WP
FAU - Walenga, J M
AU  - Walenga JM
FAU - Fu, K
AU  - Fu K
FAU - Yang, L H
AU  - Yang LH
FAU - Ing, T S
AU  - Ing TS
FAU - Herbert, J M
AU  - Herbert JM
FAU - Fareed, J
AU  - Fareed J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Oligosaccharides)
RN  - 0 (PENTA)
SB  - IM
MH  - Animals
MH  - *Clinical Laboratory Techniques
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Fibrinolytic Agents/*therapeutic use
MH  - *Models, Biological
MH  - *Monitoring, Physiologic
MH  - Oligosaccharides/*therapeutic use
MH  - *Renal Dialysis
EDAT- 1999/11/26 00:00
MHDA- 1999/11/26 00:01
CRDT- 1999/11/26 00:00
PHST- 1999/11/26 00:00 [pubmed]
PHST- 1999/11/26 00:01 [medline]
PHST- 1999/11/26 00:00 [entrez]
AID - S0049-3848(99)00094-8 [pii]
AID - 10.1016/s0049-3848(99)00094-8 [doi]
PST - ppublish
SO  - Thromb Res. 1999 Oct 15;96(2):115-24. doi: 10.1016/s0049-3848(99)00094-8.